Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038597
Status:
COMPLETED
Last Update Posted:
2018-10-30
First Post:
2002-06-03
Brief Title:
Phase II Study of SCH66336 A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia CML
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase II Study of SCH66336 A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia CML
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML The safety of this treatment will also be studied
Detailed Description:
Objectives for this study are two-fold
1 To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate duration of response and survival
2 To assess the toxicity of SCH66366 in these patients
1 To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate duration of response and survival
2 To assess the toxicity of SCH66366 in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None